Dynatrace Inc. Common Stock vs 10X Genomics Inc — how do they compare? Dynatrace Inc. Common Stock trades at $63.17 (market cap $17.66B), while 10X Genomics Inc trades at $81.9 (market cap $10.07B). The key difference: Dynatrace Inc. Common Stock is the larger of the two by market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 0 Days and 10X Genomics Inc for 92 Days on average.
| DT | TXG | |
|---|---|---|
Market Cap | $17.66B | $10.07B |
Volume | 8,779,681 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $61.12 | $97.74 |
52-Week Low | $32.36 | $11.48 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $16.71B | $9.59B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →